|
Theravance/Glaxos Asthma Drug Under FDA Panel Review
Zacks.com We note that Theravance and partner GlaxoSmithKline (GSK – Analyst Report) are seeking to expand the label of Breo Ellipta in the U.S. for the once-daily treatment of asthma in patients aged 12 years and above. A final response from the FDA is expected … FDA advisory committee to review Theravance's BREO ELLIPTA (FF/VI) for asthma |
View full post on asthma – Google News